As consolidation marches ahead in the health field, the call for stronger anti-trust reviews of potential merger is heightening.
The latest: Walgreens’ proposed purchase of mega-rival Rite Aid. Driven in large measure by the desire to combine the two retailers’ pharmacy operations, the merger has drawn considerable attention from those concerned about escalating prescription drug costs.
On the surface, the deal would seem to be a great one for all shareholders involved. Walgreens is performing well from a P&L standpoint, having just concluded a very profitable quarter and fiscal year. The Street seems to support the move: Rite Aid’s stock, which had been nearly dead, has peaked of late, and Walgreens has traded in a historically strong range.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Dan Cook
Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.
